---
title: "BUZZ-Moderna rises after US FDA agrees to review its flu vaccine"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/276227207.md"
datetime: "2026-02-18T12:26:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/276227207.md)
  - [en](https://longbridge.com/en/news/276227207.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/276227207.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/276227207.md) | [繁體中文](https://longbridge.com/zh-HK/news/276227207.md)


# BUZZ-Moderna rises after US FDA agrees to review its flu vaccine

Shares of vaccine maker Moderna (MRNA.O) up 3.1% at $45.33 premarket Co says the U.S. FDA accepted its application to review mRNA-1010, a vaccine targeting seasonal influenza using messenger RNA technology The FDA had initially refused to review the vaccine, citing flaws in the trial design MRNA says it has sought full approval for the vaccine for ages 50 to 64 years and a faster, conditional approval for those above 65 years of age with “a post-marketing requirement to conduct an additional study in older adults” Also adds that the vaccine, if approved, could be made available as early as the 2026⁄27 flu season  mRNA-1010 is also being reviewed in Europe, Canada and Australia Shares fell ~29% in 2025

### 相关股票

- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-CN/quote/FBT.US.md)
- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-CN/quote/IHE.US.md)
- [Moderna (MRNA.US)](https://longbridge.com/zh-CN/quote/MRNA.US.md)
- [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-CN/quote/IXJ.US.md)
- [VG Health (VHT.US)](https://longbridge.com/zh-CN/quote/VHT.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-CN/quote/XBI.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-CN/quote/IBB.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-CN/quote/BIB.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-CN/quote/ARKG.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-CN/quote/BBH.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-CN/quote/PBE.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-CN/quote/IBBQ.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-CN/quote/SBIO.US.md)
- [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-CN/quote/XLV.US.md)

## 相关资讯与研究

- [Regeneron Gets FDA OK for Extended Eylea HD Dosing](https://longbridge.com/zh-CN/news/281556416.md)
- [Vertex Pharmaceuticals Inc - FDA expands indication for trikafta in cf patients ages 2 and older](https://longbridge.com/zh-CN/news/281371049.md)
- [Vertex Pharmaceuticals Says US FDA Approves Label Expansion for Alyftrek, Trikafta](https://longbridge.com/zh-CN/news/281365753.md)
- [Telomir seeks FDA approval for Telomir-1 to treat breast cancer](https://longbridge.com/zh-CN/news/281346305.md)
- [BUZZ-Context Therapeutics rises as FDA grants fast-track status to ovarian cancer drug](https://longbridge.com/zh-CN/news/281517197.md)